Janssen’s MCD drug SYLVANT gets FDA approval
The drug was not evaluated in patients with MCD who are HIV positive or HHV-8 positive because it did not bind to virally produced interleukin-6 (IL-6) in a
Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta (quizartinib), an oral type II FLT3 inhibitor, in China.
The early administration of plasma has an important role in reducing battlefield mortality rates, and therefore the USAMMDA has prioritized the development of a freeze-dried plasma product. Currently,